Forbes

Merck Stock’s Ticking Keytruda Time Bomb

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...

The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer

Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
FiercePharma

Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
Hosted on MSN

Merck stock jumps as Keytruda combo trials boost cancer pipeline

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend ...
CNBC

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower ...